Cargando…

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats

We investigated the effects of esaxerenone, a novel, nonsteroidal, and selective mineralocorticoid receptor blocker, on cardiac function in Dahl salt-sensitive (DSS) rats. We provided 6-week-old DSS rats a high-salt diet (HSD, 8% NaCl). Following six weeks of HSD feeding (establishment of cardiac hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, Asadur, Sawano, Tatsuya, Sen, Anupoma, Hossain, Akram, Jahan, Nourin, Kobara, Hideki, Masaki, Tsutomu, Kosaka, Shinji, Kitada, Kento, Nakano, Daisuke, Imamura, Takeshi, Ohsaki, Hiroyuki, Nishiyama, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922950/ https://www.ncbi.nlm.nih.gov/pubmed/33669786 http://dx.doi.org/10.3390/ijms22042069

Ejemplares similares

Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats
por: Hattori, Mai, et al.
Publicado: (2022)

Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
por: Chang, Wei-Ting, et al.
Publicado: (2021)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
por: Rahman, Asadur, et al.
Publicado: (2023)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker
por: Arai, Kiyoshi, et al.
Publicado: (2020)

Oxidative Stress-Induced Glomerular Mineralocorticoid Receptor Activation Limits the Benefit of Salt Reduction in Dahl Salt-Sensitive Rats
por: Kitada, Kento, et al.
Publicado: (2012)

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
por: Tezuka, Yuta, et al.
Publicado: (2022)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
por: Munkhjargal, Uugantsetseg, et al.
Publicado: (2023)

Possible contribution of phosphate to the pathogenesis of chronic kidney disease in dolphins
por: Jahan, Nourin, et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

GLUCOCORTICOIDS ACTIVATE CARDIAC MINERALOCORTICOID RECEPTORS IN ADRENALECTOMIZED DAHL SALT-SENSITIVE RATS
por: OHTAKE, MASAFUMI, et al.
Publicado: (2014)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Responses of renal hemodynamics and tubular functions to acute sodium–glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats
por: Ansary, Tuba M., et al.
Publicado: (2017)

Regression of Glomerular and Tubulointerstitial Injuries by Dietary Salt Reduction with Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker in Dahl Salt-Sensitive Rats
por: Rafiq, Kazi, et al.
Publicado: (2014)

SUN-176 A Case of Aldosterone-Producing Adenoma with Preoperative Use of a Novel Mineralocorticoid Receptor Antagonist Esaxerenone
por: Yamanami, Hiroaki
Publicado: (2020)

Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone
por: Qiang, Panpan, et al.
Publicado: (2022)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonists and Protection Against Cardiovascular Disease in Patients with Diabetes Mellitus
por: Shimabukuro, Michio
Publicado: (2023)

A novel approach to adenine-induced chronic kidney disease associated anemia in rodents
por: Rahman, Asadur, et al.
Publicado: (2018)

Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis
por: Takagi, Nobuaki, et al.
Publicado: (2012)

Roald Dahl’s contribution to neurosurgery: the Wade-Dahl-Till shunt
por: Buis, Dennis R., et al.
Publicado: (2010)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
por: Fujimoto, Masanori, et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
por: Liu, Wenyu, et al.
Publicado: (2022)

Association of a Disrupted Dipping Pattern of Blood Pressure with Progression of Renal Injury during the Development of Salt-Dependent Hypertension in Rats
por: Sufiun, Abu, et al.
Publicado: (2020)

New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension
por: Narayan, Hafid, et al.
Publicado: (2016)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020)

The Development of Endoscopic Suturing Devices: Challenges in the Treatment of Iatrogenic Perforation and Bleeding
por: Mori, Hirohito, et al.
Publicado: (2016)

Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT(1) Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice
por: Rafiq, Kazi, et al.
Publicado: (2013)

Odd Dahl 1898 - 1994
Publicado: (1994)

Odd Dahl and the machine at CERN
por: Adams, John Bertram
Publicado: (1968)

Mechanisms of pressure-diuresis and pressure-natriuresis in Dahl salt-resistant and Dahl salt-sensitive rats
por: Beard, Daniel A, et al.
Publicado: (2012)

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
por: Nakamura, Tadakatsu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4kasvvh30nc48b71g68j177chj